AZD5363 inhibits inflammatory synergy between interleukin-17 and insulin/insulin-like growth factor 1

Frontiers in Oncology

Volumn 4, Issue DEC, 2014, Pages

  Chen, Chong ^a   Zhang, Qiuyang ^a   Liu, Sen ^a   Lambrechts, Mark ^a   Qu, Yine ^a,b   You, Zongbing ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

IGF1; IL 17; Inflammation; Insulin; Obesity; Prostate cancer

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO [2, 3 D] PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; COMPLEMENTARY DNA; CXCL1 CHEMOKINE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 17; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; INFLAMMATION; MALE; MOUSE; NONHUMAN; OBESITY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84922998037     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00343     Document Type: Article

References (55)

1. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity (2004) 21(4):467-76. doi: 10.1016/j.immuni.2004.08.018
2. Novatchkova M, Leibbrandt A, Werzowa J, Neubuser A, Eisenhaber F. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci (2003) 28(5):226-9. doi:10.1016/S0968-0004(03)00067-7
3. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem (2006) 281(47):35603-7. doi:10.1074/jbc.C600256200
4. Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol (2007) 8(3):247-56. doi:10.1038/ni1439
5. Maitra A, Shen F, Hanel W, Mossman K, Tocker J, Swart D, et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl Acad Sci U S A (2007) 104(18):7506-11. doi:10.1073/pnas.0611589104
6. Ho AW, Shen F, Conti HR, Patel N, Childs EE, Peterson AC, et al. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J Immunol (2010) 185(2):1063-70. doi:10.4049/jimmunol.0903739
7. Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Swaidani S, et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal (2009) 2(92):ra63. doi:10.1126/scisignal.2000382
8. Ge D, Dauchy RT, Liu S, Zhang Q, Mao L, Dauchy EM, et al. Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin's anti-inflammatory action. J Pineal Res (2013) 55(4):377-87. doi:10.1111/jpi.12084
9. Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med (2012) 18(7):1077-86. doi:10.1038/nm.2815
10. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther (2004) 6(2):R120-8. doi:10.1186/ar1038
11. Bulek K, Liu C, Swaidani S, Wang L, Page RC, Gulen MF, et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol (2011) 12(9):844-52. doi:10.1038/ni.2080
12. Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol (2011) 12(9):853-60. doi:10.1038/ni.2081
13. Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology (1980) 107(4):1176-81. doi:10.1210/endo-107-4-1176
14. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 21(10):610-8. doi:10.1016/j.tem.2010.06.007
15. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995) 378(6559):785-9. doi:10.1038/378785a0
16. Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J (1994) 303(Pt 1):21-6.
17. Chiara F, Rasola A. GSK-3 and mitochondria in cancer cells. Front Oncol (2013) 3:16. doi:10.3389/fonc.2013.00016
18. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem (2004) 279(4):2559-67. doi:10.1074/jbc.M308809200
19. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem (2006) 281(34):24138-48. doi:10.1074/jbc.M604597200
20. Shen F, Li N, Gade P, Kalvakolanu DV, Weibley T, Doble B, et al. IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal (2009) 2(59):ra8. doi:10.1126/scisignal.2000066
21. Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem (2003) 278(41):39583-90. doi:10.1074/jbc.M305676200
22. Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, et al. Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models. Eur Urol (2014). doi:10.1016/j.eururo.2014.08.006
23. Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res (2013) 19(4):833-44. doi:10.1158/1078-0432.CCR-12-3114
24. Yung HW, Charnock-Jones DS, Burton GJ. Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One (2011) 6(3):e17894. doi:10.1371/journal.pone.0017894
25. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 24(50):7455-64. doi:10.1038/sj.onc.1209085
26. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 94:29-86. doi:10.1016/S0065-230X(05)94002-5
27. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther (2012) 11(4):873-87. doi:10.1158/1535-7163.MCT-11-0824-T
28. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 15(23):6541-51.
29. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol (1997) 7(4):261-9. doi:10.1016/S0960-9822(06)00122-9
30. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307(5712):1098-101. doi:10.1126/science.1106148
31. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 406(6791):86-90. doi:10.1038/35017574
32. Chen C, Khismatullin DB. Lipopolysaccharide induces the interactions of breast cancer and endothelial cells via activated monocytes. Cancer Lett (2014) 345(1):75-84. doi:10.1016/j.canlet.2013.11.022
33. Couzin-Frankel J. Inflammation bares a dark side. Science (2010) 330(6011):1621. doi:10.1126/science.330.6011.1621
34. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
35. Zhang Q, Liu S, Ge D, Xue Y, Xiong Z, Abdel-Mageed AB, et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res (2012) 72(10):2589-99. doi:10.1158/0008-5472.CAN-11-3795
36. Zhang Q, Liu S, Xiong Z, Wang AR, Myers L, Melamed J, et al. Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate (2014) 74(8):869-79. doi:10.1002/pros.22805
37. Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, et al. Obesity predisposes to Th17 bias. Eur J Immunol (2009) 39(9):2629-35. doi:10.1002/eji.200838893
38. Pini M, Fantuzzi G. Enhanced production of IL-17A during zymosan-induced peritonitis in obese mice. J Leukoc Biol (2010) 87(1):51-8. doi:10.1189/jlb.0309188
39. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond) (2009) 33(1):151-6. doi:10.1038/ijo.2008.216
40. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer (2012) 19(5):F27-45. doi:10.1530/ERC-11-0374
41. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer (2003) 45(1):1-16. doi:10.1207/S15327914NC4501_1
42. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev (2002) 11(12):1531-43.
43. Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal caner. J Gastrointest Oncol (2012) 3(3):226-31. doi:10.3978/j.issn.2078-6891.2012.026
44. Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog (2012) 51(1):53-63. doi:10.1002/mc.20778
45. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev (2007) 16(12):2533-47. doi:10.1158/1055-9965.EPI-07-0708
46. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med (2000) 343(18):1305-11. doi:10.1056/NEJM200011023431804
47. Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev (2011) 20(3):464-72. doi:10.1158/1055-9965.EPI-10-1220
48. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer (2007) 96(9):1457-61. doi:10.1038/sj.bjc.6603703
49. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2004) 22(3):439-45. doi:10.1200/JCO.2004.03.132
50. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 14(18):1650-6. doi:10.1016/j.cub.2004.08.026
51. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 19(15):1773-8. doi:10.1101/gad.1314605
52. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 431(7005):200-5. doi:10.1038/nature02866
53. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 166(2):213-23. doi:10.1083/jcb.200403069
54. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 66(3):1500-8. doi:10.1158/0008-5472.CAN-05-2925
55. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 5(7):484-93. doi:10.1038/nchembio.183